glp-1 drug exposure pharmaceutical companies 2025 Chart: 1 in 8 Americans Now Use Drugs for Weight Loss GLP-1 Drug Manufacturing Simplified: SAP

Evidence shows that most people regain weight once they stop taking these drugs, and we cannot medicate two-thirds of the population indefinitely, added Jenner.

We do not assure the accuracy of the information on Pandameds.com and cannot be held liable for any actions taken based on this information

Therefore, this compound seems to be not solely a new antidiabetic medication

PLoS Genet 19 , e1010710 (2023)

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study